How the themes are counted
One paper saying "this needs more study" tells you little. 52 separate papers raising the same open question is a finding about the field. The themes below are ordered by how many distinct papers raised them, most first, with "Other open questions" last. We count papers, not sentences, because one long paper can produce a dozen sentences on the same point.
Of the 369 studies in the library, 253 yielded at least one such sentence (455 from open-access full text, 49 from the abstract only). The rest either had no accessible text, or simply did not phrase an open question in a way we could quote without interpreting it — and we would rather miss one than invent one.
- The mechanism is not understood 52
- Measurement, definitions, assays and standardisation 51
- Real-world delivery, cost and access 51
- Who was studied - diversity and generalisability 49
- Biomarker-defined, genetic and clinical subgroups 47
- Follow-up is too short to know if the effect lasts 42
- Bigger samples and independent replication 27
- Specific exposures, drugs and programmes named as worth testing 25
- Whether the association is causal is still open 18
- Long-term safety and harms 14
- The right dose, intensity, frequency and type is unresolved 13
- When in life to intervene 13
- Better treatments and interventions still need developing 2
- Combination and multidomain approaches 1
- Other open questions 35
Where the papers disagree
These are not gaps everyone agrees on. In each pair below, two papers in this library point in different directions about what should happen next. Both quotes are verbatim.
Physical activity: is the open question whether it works, or which kind works best?
“Furthermore, our results on cognitive decline are in accordance with other longitudinal studies showing no association between physical activity and cognitive ageing.”
Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study. · BMJ, 2017
“Future studies are needed to confirm current findings, explore the effects of different types of exercise training on outcomes in individuals with SVCI, identify moderators of exercise efficacy (e.g., biological sex), and examine the distinct mechanisms by which each exercise modality may exert its benefits.”
Resistance training and subcortical vascular cognitive impairment: A 12-month randomized trial. · Alzheimer's & Dementia, 2026
Both papers are asking for more exercise research, but not the same research. One reports no association with cognitive decline at all; the other treats the benefit as established enough that the next question is which modality and which mechanism.
Vision and hearing: replicate the association first, or start rolling out screening?
“While some US cohort studies have observed a significant association between vision impairment and dementia risk [ , ], other US and European longitudinal studies have failed to replicate these findings [ – ].”
“Future studies should test whether vision screening or cataract surgery in those with co-occurring dementia risk factors are effective at reducing the risk of dementia.”
Visual Impairment, Eye Conditions, and Diagnoses of Neurodegeneration and Dementia. · JAMA Network Open, 2024
The same body of evidence is read two ways: one review notes that the vision-dementia association has failed to replicate across cohorts, while the proposed next steps elsewhere assume it holds and move to testing or implementing screening.
Repeat scans and tests to monitor disease: not supported, or the obvious next study?
“Cross‐sectional and longitudinal studies do not support the use of a subsequent amyloid PET to assess the degree of cognitive impairment or to monitor the rate of progression of the underlying AD pathological process.”
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. · Alzheimer's & Dementia, 2025
“Additionally, future research should explore how the test can monitor disease as it progresses or how treatment responds with longitudinal studies [ ] .”
FDA approval of the Lumipulse G PTau217/β-amyloid 1-42 plasma ratio test: a new era in accessible Alzheimer's diagnosis. · Annals of Medicine and Surgery, 2025
The appropriate-use criteria for amyloid and tau PET state that the existing longitudinal evidence does not support repeat amyloid imaging for monitoring. An editorial on the newly approved blood test proposes studying exactly that use for blood biomarkers. Different tests - but the same unresolved question about whether repeat measurement tracks anything useful.
The mechanism is not understood 52 papers
The effect is measurable; the biology behind it is not settled. — 58 quoted sentences from 52 separate papers.
-
“Further study of CAA‐ri may therefore offer a valuable model for exploring the pathophysiological mechanisms of ARIA.”
— Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup.; van Etten ES, et al.; Alzheimer's & Dementia, 2026. review Spontaneous hemorrhages and edema · source text
-
“Though the mechanism remains unclear, ARM may act as a defense against beta-amyloid accumulation through barrier formation and increased phagocytosis.”
— APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer's disease.; Nguyen AT, Wang K, Hu G, Wang X, Miao Z, Azevedo JA, Suh E, Van Deerlin VM, Choi D, Roeder K, Li M, Lee EB; Acta Neuropathologica, 2020. Discussion · source text
-
“Lastly, starting from our results, future studies need to more deeply explore the underlying biological mechanisms through which the MedDiet may influence dementia, and therefore comparing the effectiveness of the MedDiet with other dietary patterns in reducing the risk of dementia.”
— Association between Mediterranean diet and dementia and Alzheimer disease: a systematic review with meta-analysis.; Nucci D, Sommariva A, Degoni LM, Gallo G, Mancarella M, Natarelli F, et al.; Aging Clinical and Experimental Research, 2024. meta-analysis Implications for policy, practice and future research · source text
-
“Future studies are needed to better elucidate these mechanisms.”
— Long-term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies: An up to 10-year follow-up study.; Xu H, Habich A, Ferreira D, Elisabet L, Westman E, Eriksdotter M; Alzheimer's & Dementia, 2024. DISCUSSION · source text
-
“The role of prolonged sleep duration in the development of dementia remains unclear and is closely associated with age.”
— Sleep disorders and the risk of cognitive decline or dementia: an updated systematic review and meta-analysis of longitudinal studies.; Zhang J, Ou J, Lu X, Wang T, Dang W, Ding L, Liu Y, Xu J, Yan B, Yu H; Journal of Neurology, 2025. meta-analysis Sleep duration and cognitive disorders · source text
-
“Further research into the interaction between diet and genetics on dementia risk is therefore warranted.”
— Mediterranean diet adherence is associated with lower dementia risk, independent of genetic predisposition: findings from the UK Biobank prospective cohort study.; Shannon OM, Ranson JM, Gregory S, Macpherson H, Milte C, Lentjes M, et al.; BMC Medicine, 2023. Discussion · source text
Show the other 52 quotes in this theme
-
“Nevertheless, the evolution of plasma GFAP in relation to brain Aβ/tau burden, as well as the exact interaction between astrocyte activation and Aβ deposition in the advanced pathological stages of AD, warrants further investigation.”
— Plasma P-tau217, GFAP, and NfL as biomarkers for Alzheimer's disease: role in disease stratification, pathological progression, and cognitive decline.; Alzheimer's & Dementia, 2025. BACKGROUND
-
“Thus, higher HDL-cholesterol and triglyceride levels regulated by apoE2 might both contribute to APOE2 -mediated longevity although further study is necessary to confirm such findings and address the potential underlying mechanisms.”
— APOE2 is associated with longevity independent of Alzheimer's disease.; eLife, 2020. Discussion
-
“Future studies will need to confirm underlying mechanisms and should investigate other eye diseases (observationally and in MR studies), including diabetic retinopathy, optic neuropathy, and other vascular causes of eye disease.”
— Visual Impairment, Eye Conditions, and Diagnoses of Neurodegeneration and Dementia.; JAMA Network Open, 2024. Discussion
-
“Further research is needed to explore these potential mechanisms, as they were beyond the scope of this trial.”
— Resistance training and subcortical vascular cognitive impairment: A 12-month randomized trial.; Alzheimer's & Dementia, 2026. DISCUSSION
-
“Differences in the association between delirium and incident dementia in men and women reinforce the need to not only adjust for gender in future studies but also to look for gender specific associations that might have important mechanistic and clinical implications.”
— Delirium and incident dementia in hospital patients in New South Wales, Australia: retrospective cohort study.; BMJ, 2024. Conclusions
-
“Further research is warranted to explore the specific mechanisms underlying the association between MVPA and other risk factors.”
— Dose- and pattern- physical activity is associated with lower risk of dementia.; Journal of Prevention of Alzheimer's Disease, 2025. Discussion
-
“In addition, the mechanisms underlying the association between alcohol and cognitive aging remain unclear.”
— Alcohol consumption and risk of dementia: 23 year follow-up of Whitehall II cohort study.; BMJ, 2018. Introduction
-
“The relationship between NAA and ADRD's risk, mediated or not by APOE , will require further studies to be fully understood.”
— APOE and Alzheimer's disease and related dementias risk among 12,221 Hispanics/Latinos.; Alzheimer's & Dementia, 2025. DISCUSSION
-
“Future work to probe the mechanisms behind observed differences seen by sex, race/ethnicity, and neighborhood socioeconomic status could be conducted through analysis of longitudinal cohort studies with information on both cognitive outcomes and detailed life course history.”
— Incidence and prevalence of dementia among US Medicare beneficiaries, 2015-21: population based study.; BMJ, 2025. Unanswered questions and future research
-
“Together, these clinical data highlight a T-cell mediated mechanism that may inform future studies and aid in the development of safer and more effective therapeutics for the highest risk AD populations.”
— Clonal expansion of cytotoxic CD8⁺ T cells in lecanemab-associated ARIA.; Nature Communications, 2026. Introduction
-
“It is important for future studies to determine the potential modifying role of HT on the association of p-tau217 with dementia.”
— Plasma Phosphorylated Tau 217 and Incident Mild Cognitive Impairment and Dementia in Older Women.; JAMA Network Open, 2026. Discussion
-
“Furthermore, the ARM response is reduced in the setting of sporadic AD genetic risk variants such as TREM2 R47H and APOE E4. While it is plausible that the ARM response to beta-amyloid plaques is protective, the precise mechanism remains unclear.”
— APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer's disease.; Acta Neuropathologica, 2020. Discussion
-
“Although several potential biological pathways have been identified, the mechanisms underlying the association between sleep duration and cognitive decline remain unclear.”
— Sleep disorders and the risk of cognitive decline or dementia: an updated systematic review and meta-analysis of longitudinal studies.; Journal of Neurology, 2025. Sleep duration and cognitive disorders
-
“Future studies are needed to confirm current findings, explore the effects of different types of exercise training on outcomes in individuals with SVCI, identify moderators of exercise efficacy (e.g., biological sex), and examine the distinct mechanisms by which each exercise modality may exert its benefits.”
— Resistance training and subcortical vascular cognitive impairment: A 12-month randomized trial.; Alzheimer's & Dementia, 2026. DISCUSSION
-
“Additionally, various factors, such as changes in educational attainment and risk factor burden, particularly the burden of cerebrovascular disease, which is strongly linked with dementia risk, may have implications for the epidemiology of dementia, in both the general population and specific subgroups, such as among beneficiaries from socioeconomically deprived neighborhoods, and deserve future study to delve into potential underlying mechanisms.”
— Incidence and prevalence of dementia among US Medicare beneficiaries, 2015-21: population based study.; BMJ, 2025. Unanswered questions and future research
-
“Our findings suggest a potential moderating role of age, race, APOE ε4, and HT in the associations between p-tau217 and cognitive outcomes; further studies are needed to confirm these findings.”
— Plasma Phosphorylated Tau 217 and Incident Mild Cognitive Impairment and Dementia in Older Women.; JAMA Network Open, 2026. Conclusions
-
“The converse question – whether impaired overnight Aβ and tau clearance leads to increased AD pathological burden and long-term shifts in steady-state plasma AD biomarker levels—is a compelling hypothesis that requires a further investigation.”
— The glymphatic system clears amyloid beta and tau from brain to plasma in humans; Nature Communications, 2026. discussion
-
“Future studies are needed to better evaluate the pathophysiologic role of kidney dysfunction in the studied associations and to assess the extent to which it affects the clinical validity of AD blood biomarkers.”
— Kidney Function, Alzheimer Disease Blood Biomarkers, and Dementia Risk in Community-Dwelling Older Adults; Neurology, 2026. discussion
-
“Future studies should investigate whether additional genes and pathways within the Lecanemab-induced pink module contribute to amyloid clearance, and whether this transcriptional profile represents an amplification of known DAM/HLA microglia cell states or defines a distinct microglial phenotype with enhanced amyloid-clearing capacity.”
— The Alzheimer's therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-clearing program in microglia; Nature Neuroscience, 2026. discussion
-
“It is unknown how the gain-of-function Trem2T96K mutation results in similar disease phenotypes as loss-of-function Trem2 mutations and leads to AD.”
— The gain-of-function TREM2-T96K mutation increases risk for Alzheimer's disease by impairing microglial function; Neuron, 2026. discussion
-
“To elucidate the biological mechanisms underlying our findings, future research integrating biomarkers with phenotypically characterized glial cells is needed to better understand the neuroinflammatory response in AD.”
— Microglia modulate Aβ-dependent astrocyte reactivity in Alzheimer's disease; Nature Neuroscience, 2026. discussion
-
“Thus, future studies combining CSF biomarkers, advanced neuroimaging, and measures of BBB permeability will be important to clarify the extent to which peripheral complement alterations track CNS complement activity.”
— Systemic complement factors in aging, Alzheimer's disease and other dementias: a longitudinal study over 10 years; Molecular Neurodegeneration, 2026. discussion
-
“Future studies integrating brain multi-omics with AD biomarkers across disease stages and functional validation may further distinguish central from peripheral origins and establish causal roles in AD risk.”
— Proteomic signatures of the APOE ε4 and APOE ε2 genetic variants and Alzheimer's disease; Nature Aging, 2026. discussion
-
“The combination of these results suggests that our novel prioritized genes may indeed affect AD through immune pathways, although it is unclear whether that is specifically related to the function of microglial activation and autophagy.”
— Novel early-onset Alzheimer-associated genes influence risk through dysregulation of glutamate, immune activation, and intracellular signaling pathways; Alzheimer's & Dementia, 2025. other
-
“How Arc interacts with tau inside the cell prior to EV biogenesis to regulate tau aggregation, and whether this occurs in a liquid-liquid phase separated compartment, should be addressed in future studies.”
— Arc mediates intercellular tau transmission via extracellular vesicles; Cell, 2026. discussion
-
“Whether tau seeds isolated from MF in PART and ADNC at these early Braak stages (≤ IV) are derived from seeds that spread from the medial temporal lobe or from nucleation events within the neocortex remains unclear.”
— Early Alzheimer's Disease with frequent neuritic plaques harbors neocortical tau seeds distinct from primary age-related tauopathy; Nature Communications, 2025. discussion
-
“First, the mechanism by which APOEε4 enhances FN1 requires further investigations.”
— Rare genetic variation in fibronectin 1 (FN1) protects against APOEε4 in Alzheimer's disease; Acta Neuropathologica, 2024. discussion
-
“However, noting that different Aβ species have been observed in the brains of AD patients, it is not clear which of these species are neurotoxic, thereby potentially limiting the therapeutic benefit of these approaches.”
— APP antisense oligonucleotides reduce amyloid-β aggregation and rescue endolysosomal dysfunction in Alzheimer's disease; Brain, 2024. discussion
-
“However, to understand these intricate relationships, studies incorporating a more comprehensive sampling of diverse brain regions at various disease stages are warranted.”
— Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles; Brain, 2024. discussion
-
“An important goal for future studies will be to confirm the relationship between NE release and brain solute clearance in humans, and assess how compromised sleep and stiffening of the cerebral vasculature affect brain clearance in aging and disease states.”
— Norepinephrine-mediated slow vasomotion drives glymphatic clearance during sleep; Cell, 2025. discussion
-
“Another question that remains to be answered is if and how REM sleep influences glymphatic flow.”
— Norepinephrine-mediated slow vasomotion drives glymphatic clearance during sleep; Cell, 2025. discussion
-
“Given the regional heterogeneity of glymphatic activity and the potentially heterogeneous effects of aggregated protein toxicity throughout the brain, studies investigating regional glymphatic function in AD‐susceptible networks are needed.”
— Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease; Alzheimer's & Dementia, 2024. discussion
-
“How CD8+ T cells communicate with neuronal cells and potentially induce deleterious effects in AD is unclear.”
— CD103-CD8+ T cells promote neurotoxic inflammation in Alzheimer's disease via granzyme K-PAR-1 signaling; Nature Communications, 2025. discussion
-
“The mechanistic basis behind the lower ARIA‐E frequency in the modified titration arm is yet to be determined.”
— Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction; Alzheimer's & Dementia, 2025. discussion
-
“Further studies are needed to determine if UFMylation-enhanced Tau propagation is mediated by ER stress/ER-phagy, ribosomal quality control, or other unknown mechanisms.”
— Human iPSC 4R tauopathy model uncovers modifiers of tau propagation; Cell, 2024. discussion
-
“The reasons for this are not clearly known, and the relative frequency of subtypes of M-NCD for which these drugs are not indicated cannot explain it.”
— Cholinesterase inhibitors and memantine are associated with a reduced mortality in nursing home residents with dementia: a longitudinal observational study; Alzheimer's Research & Therapy, 2024. discussion
-
“Other than investing into randomized trials, investments into basic science research on the potential role of VZV and the immune response to the zoster vaccine in the pathogenesis of dementia could provide critical mechanistic insights.”
— A natural experiment on the effect of herpes zoster vaccination on dementia (Wales); Nature, 2025. discussion
-
“The biological mechanisms underlying these associations remain unclear.”
— Association between plant-based diets and incident dementia: results from prospective cohort studies and a meta-analysis; The journal of prevention of Alzheimer's disease, 2026. discussion
-
“We cannot rule out the possibility that other factors, including additional variants, may have contributed to the AD resilience phenotype in RELN-COLBOS carriers.”
— Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man; Nature Medicine, 2023. discussion
-
“However, beyond the identification of more dementia-associated variants from GWASs (most of them are common variants), more studies are required to better understand the role of rare and structural variants for dementia,– which also need to be incorporated in risk-prediction models.”
— Validation of newly derived polygenic risk scores for dementia in a prospective study of older individuals; Alzheimer's & Dementia, 2023. discussion
-
“Assessment of linkage disequilibrium and/or an interaction effect of the APOECh variant with other AD-protective variants to establish the mechanism by which heterozygous carriers may have a protective effect is an important next step.”
— Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants; Molecular Neurodegeneration, 2023. other
-
“Future analyses of brain MRI and social engagement data that were collected in the ACHIEVE study will allow for further elucidation of the pathways through which hearing intervention may reduce cognitive decline.”
— Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial; The Lancet, 2023. discussion
-
“Future work should define whether sleep disturbances that preceded the clinical diagnosis contribute to aggregate seeding and whether the sleep disturbances during disease progression accelerate the aggregate spread.”
— Glymphatic failure as a final common pathway to dementia; Science, 2020. other
-
“However, it also emphasizes our incomplete understanding of the observed temporal trend and the need for further exploration of factors that contribute to this decline in order to better understand and possibly accelerate this beneficial trend.”
— Incidence of Dementia over Three Decades in the Framingham Heart Study; New England Journal of Medicine, 2016. discussion
-
“However, the full set of social, behavioral, and medical factors contributing to the decline in dementia prevalence is still uncertain.”
— A Comparison of the Prevalence of Dementia in the United States in 2000 and 2012; JAMA Internal Medicine, 2017. discussion
-
“Third, gene–gene and gene–environment interactions have not yet been studied in detail.”
— New insights into the genetic etiology of Alzheimer's disease and related dementias; Nature Genetics, 2022. discussion
-
“It will be important in future studies to examine whether this microglia or the complement-dependent pathway also plays a role in plaque-associated synapse loss or in other synaptopathies including tauopathies and Huntington's disease.”
— Complement and microglia mediate early synapse loss in Alzheimer mouse models; Science, 2016. other
-
“Many important questions remain to be answered, among them: -What instigates Aβ aggregation in sAD?”
— Three dimensions of the amyloid hypothesis: time, space and 'wingmen'; Nature Neuroscience, 2015. conclusion
-
“Further research is needed on other pathways through which lower educational attainment leads to higher dementia risk in order to inform the development of equitable prevention strategies.”
— Educational Attainment and Dementia: Mediation by Mid-Life Vascular Risk Factors; Annals of Neurology, 2023. discussion
-
“The relationship of NfL to tau in bodily fluids needs further work.”
— Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease; Nature Medicine, 2019. other
-
“Gaining a better understanding of AD pathogenesis will require a framework that mechanistically interlinks all these phenomena.”
— Alzheimer's Disease is Type 3 Diabetes-Evidence Reviewed; Journal of Diabetes Science and Technology, 2008. abstract only
-
“support routine delirium assessment on hospital admission for all older adults and highlight the need to further investigate neurodegenerative mechanisms in delirium.”
— Delirium, long-term conditions, and incident dementia in older adults admitted to hospital for emergency care in Lothian, Scotland: a population-based cohort study; The lancet. Healthy longevity, 2026. abstract only
Measurement, definitions, assays and standardisation 51 papers
Different teams measuring different things and calling them the same name. — 57 quoted sentences from 51 separate papers.
-
“Though it identified many reasons to involve specialist palliative care, the lack of consensus highlighted the need for further study on a set of consensus referral criteria that may streamline referrals to specialist palliative care in a timely manner to optimize patient and caregiver outcomes.”
— Referral Criteria for Specialist Palliative Care for Patients With Dementia.; Chang YK, Philip J, van der Steen JT, Van den Block L, Hum AYM, Pérez-Cruz PE, Paiva C, Mori M, Chen PJ, Agar MR, et al.; JAMA Network Open, 2025. Introduction · source text
-
“The relative roles of SWI versus GRE for the detection of microhemorrhages warrant further evaluation.”
— Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup.; van Etten ES, et al.; Alzheimer's & Dementia, 2026. review Outstanding challenges and future directions · source text
-
“Future studies should use modeling techniques that can better account for these other types of societal costs.”
— Cost of care for Alzheimer's disease and related dementias in the United States: 2016 to 2060.; Nandi A, Counts N, Bröker J, Malik S, Chen S, Han R, Klusty J, Seligman B, Tortorice D, Vigo D, Bloom DE; npj Aging, 2024. Discussion · source text
-
“Although we found some evidence of differences in hazards for stroke, pneumonia, and acute kidney injury between male and female antipsychotic users, further research is needed to validate these findings.”
— Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study.; Mok PLH, Carr MJ, Guthrie B, Morales DR, Sheikh A, Elliott RA, Camacho EM, van Staa T, Avery AJ, Ashcroft DM; BMJ, 2024. Strengths and limitations of this study · source text
-
“Future studies should aim to adopt standardized diagnostic frameworks incorporating objective sleep measures (e.g., polysomnography or actigraphy) to minimize variability in sleep disorder definitions.”
— Sleep disorders and the risk of cognitive decline or dementia: an updated systematic review and meta-analysis of longitudinal studies.; Zhang J, Ou J, Lu X, Wang T, Dang W, Ding L, Liu Y, Xu J, Yan B, Yu H; Journal of Neurology, 2025. meta-analysis Publication bias and heterogeneity · source text
-
“If future studies confirm that Aβ positivity affects SAA results, it is then crucial to develop SAA protocols that are robust to Aβ co-pathology.”
— Diagnostic Performance of the α-Synuclein Seed Amplification Assay for Dementia With Lewy Bodies: A Comparison Across 4 Laboratories.; Kumar R, Gravett S, Jelic V, Lange J, Oftedal L, Ciullini A, Bacınoğlu MB, De Luca CMG, Hamied L, Birck C, et al.; Neurology, 2026. Discussion · source text
Show the other 51 quotes in this theme
Real-world delivery, cost and access 51 papers
Whether a result that held in a trial survives contact with an ordinary clinic. — 52 quoted sentences from 51 separate papers.
-
“Further research is necessary not only to validate their use in the primary and specialist care settings but also to evaluate for possible impediments to effective implementation.”
— Referral Criteria for Specialist Palliative Care for Patients With Dementia.; Chang YK, Philip J, van der Steen JT, Van den Block L, Hum AYM, Pérez-Cruz PE, Paiva C, Mori M, Chen PJ, Agar MR, et al.; JAMA Network Open, 2025. Discussion · source text
-
“Clinicians will need to be prepared to engage in a multistep process of evaluating appropriateness for treatment, with each step involving education and counseling.”
— Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup.; van Etten ES, et al.; Alzheimer's & Dementia, 2026. review RISK/BENEFIT CONVERSATIONS IN TREATMENT DECISION‐MAKING AND PATIENT PERSPECTIVE · source text
-
“Future studies should use modeling techniques that can better account for these other types of societal costs.”
— Cost of care for Alzheimer's disease and related dementias in the United States: 2016 to 2060.; Nandi A, Counts N, Bröker J, Malik S, Chen S, Han R, Klusty J, Seligman B, Tortorice D, Vigo D, Bloom DE; npj Aging, 2024. Discussion · source text
-
“Further research is needed into safer drug treatment of behavioural and psychological symptoms of dementia and more efficacious, easy to deliver, initial non-drug treatments.”
— Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study.; Mok PLH, Carr MJ, Guthrie B, Morales DR, Sheikh A, Elliott RA, Camacho EM, van Staa T, Avery AJ, Ashcroft DM; BMJ, 2024. Policy implications · source text
-
“The next steps will be to establish the most effective, cost-effective, and feasible strategies for reducing these risks, that can be sustained within local contexts and achieve the best impacts, at the population level, in the short, medium, and long term.”
— Population attributable fractions of modifiable risk factors for dementia: a systematic review and meta-analysis.; Stephan BCM, Cochrane L, Kafadar AH, Brain J, Burton E, Myers B, et al.; Lancet Healthy Longevity, 2024. meta-analysis Discussion · source text
-
“Future studies should, where possible, incorporate objective measures of hearing aid benefit—such as aided audiometry, speech-in-noise tests, or even real-world data logging of device use—to validate and extend our findings based on self-report.”
— Hearing aid effectiveness and probable dementia risk across 33 countries: A pooled analysis of seven cohorts.; Jiang F, Dong Q, Jayakody DMP, Chen X, Mueller C, Wu B, et al.; Cell Reports Medicine, 2026. Discussion · source text
Show the other 46 quotes in this theme
Who was studied - diversity and generalisability 49 papers
Authors flag that their sample was narrow and that the result may not transfer. — 52 quoted sentences from 49 separate papers.
-
“Overall, the results highlight that interventions will not only need to be tailored to different countries but also to the unique risk profiles and needs of different groups within countries.”
— Population attributable fractions of modifiable risk factors for dementia: a systematic review and meta-analysis.; Stephan BCM, Cochrane L, Kafadar AH, Brain J, Burton E, Myers B, et al.; Lancet Healthy Longevity, 2024. meta-analysis Discussion · source text
-
“Further research across diverse global settings, particularly in low-resource settings, is essential to confirm these findings and guide tailored interventions.”
— Hearing aid effectiveness and probable dementia risk across 33 countries: A pooled analysis of seven cohorts.; Jiang F, Dong Q, Jayakody DMP, Chen X, Mueller C, Wu B, et al.; Cell Reports Medicine, 2026. Limitations of the study · source text
-
“The precise underlying causes are uncertain and require further study, extending also to underrepresented regions such as low and middle income countries.”
— Time to nursing home admission and death in people with dementia: systematic review and meta-analysis.; Brück CC, Mooldijk SS, Kuiper LM, Sambou ML, Licher S, Mattace-Raso F, Wolters FJ; BMJ, 2025. meta-analysis Geographical and temporal differences in prognosis · source text
-
“Future work should aim to reproduce our findings with larger, and more representative, diverse samples.”
— APOE and Alzheimer's disease and related dementias risk among 12,221 Hispanics/Latinos.; Barral S, Yang Z, Phillips N, Barber RC, Brickman AM, Honig LS, Cieza B, Reyes-Dumeyer D, Mayeux R, Rajabli F, et al.; Alzheimer's & Dementia, 2025. DISCUSSION · source text
-
“However, future work should validate the test in diverse groups to realize its full clinical use.”
— FDA approval of the Lumipulse G PTau217/β-amyloid 1-42 plasma ratio test: a new era in accessible Alzheimer's diagnosis.; Biruk D. Ayalew, Zemichael G. Alemayehu, Tsimona D. Bonger, Brook L. Sime, Yonatan A. Zewdie, Yeamlak T. Tewodros, Sher Bano; Annals of Medicine and Surgery, 2025. editorial Future directions and recommendations · source text
-
“Finally, this study did not formally assess potential interactions between age, race/ethnicity, sex, neighborhood deprivation, and dementia incidence or prevalence, and future work to disentangle intersectionality in these dimensions is clearly needed.”
— Incidence and prevalence of dementia among US Medicare beneficiaries, 2015-21: population based study.; Blass B, Ford CB, Soneji S, Zepel L, Rosa TD, Kaufman BG, Mantri S, Li F, Mac Grory B, Xian Y, et al.; BMJ, 2025. Strengths and weaknesses of study · source text
Show the other 46 quotes in this theme
Biomarker-defined, genetic and clinical subgroups 47 papers
Who benefits, not just whether anyone does. — 56 quoted sentences from 47 separate papers.
-
“While the link between APOE ε2 and ARIA risk remains to be elucidated, these observations suggest that APOE ε2 status may need to be factored into individual risk assessment of hemorrhagic complications following ATTs.”
— Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup.; van Etten ES, et al.; Alzheimer's & Dementia, 2026. review Role of immune responses, CAA‐ri, and APOE genotype · source text
-
“Furthermore, the ARM response is reduced in the setting of sporadic AD genetic risk variants such as TREM2 R47H and APOE E4. While it is plausible that the ARM response to beta-amyloid plaques is protective, the precise mechanism remains unclear.”
— APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer's disease.; Nguyen AT, Wang K, Hu G, Wang X, Miao Z, Azevedo JA, Suh E, Van Deerlin VM, Choi D, Roeder K, Li M, Lee EB; Acta Neuropathologica, 2020. Discussion · source text
-
“In this respect, further research is needed to assess differences between the two sexes in elderly people.”
— Association between Mediterranean diet and dementia and Alzheimer disease: a systematic review with meta-analysis.; Nucci D, Sommariva A, Degoni LM, Gallo G, Mancarella M, Natarelli F, et al.; Aging Clinical and Experimental Research, 2024. meta-analysis Discussion · source text
-
“If future studies confirm that Aβ positivity affects SAA results, it is then crucial to develop SAA protocols that are robust to Aβ co-pathology.”
— Diagnostic Performance of the α-Synuclein Seed Amplification Assay for Dementia With Lewy Bodies: A Comparison Across 4 Laboratories.; Kumar R, Gravett S, Jelic V, Lange J, Oftedal L, Ciullini A, Bacınoğlu MB, De Luca CMG, Hamied L, Birck C, et al.; Neurology, 2026. Discussion · source text
-
“Overall, the results highlight that interventions will not only need to be tailored to different countries but also to the unique risk profiles and needs of different groups within countries.”
— Population attributable fractions of modifiable risk factors for dementia: a systematic review and meta-analysis.; Stephan BCM, Cochrane L, Kafadar AH, Brain J, Burton E, Myers B, et al.; Lancet Healthy Longevity, 2024. meta-analysis Discussion · source text
-
“Sex and gender differences should be carefully considered in future studies examining the association or effect of olive oil on cognitive-related outcomes to improve our understanding.”
— Consumption of Olive Oil and Diet Quality and Risk of Dementia-Related Death.; Tessier AJ, Cortese M, Yuan C, Bjornevik K, Ascherio A, Wang DD, Chavarro JE, Stampfer MJ, Hu FB, Willett WC, et al.; JAMA Network Open, 2024. Discussion · source text
Show the other 50 quotes in this theme
Follow-up is too short to know if the effect lasts 42 papers
Papers repeatedly say their own follow-up window cannot answer whether a benefit persists. — 51 quoted sentences from 42 separate papers.
-
“In fact, longitudinal studies may be prone to selection bias, especially in the elderly population, who may be lost to follow-up for various reasons, including death.”
— Association between Mediterranean diet and dementia and Alzheimer disease: a systematic review with meta-analysis.; Nucci D, Sommariva A, Degoni LM, Gallo G, Mancarella M, Natarelli F, et al.; Aging Clinical and Experimental Research, 2024. meta-analysis Discussion · source text
-
“Furthermore, our results on cognitive decline are in accordance with other longitudinal studies showing no association between physical activity and cognitive ageing.”
— Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study.; Sabia S, Dugravot A, Dartigues JF, Abell J, Elbaz A, Kivimäki M, Singh-Manoux A; BMJ, 2017. Strengths and limitations of study · source text
-
“Many studies of cognitive impairment due to RBD and circadian rhythm are extremely small for a comprehensive evaluation, and further longitudinal studies are warranted in the future.”
— Sleep disorders and the risk of cognitive decline or dementia: an updated systematic review and meta-analysis of longitudinal studies.; Zhang J, Ou J, Lu X, Wang T, Dang W, Ding L, Liu Y, Xu J, Yan B, Yu H; Journal of Neurology, 2025. meta-analysis Other sleep disorders and cognitive disorders · source text
-
“Future studies may benefit from strategies to support sustained engagement, such as enhanced technical support and additional check-ins to address challenges.”
— Digital Reminiscence for Predeath Grief Among Family Caregivers of Patients With Dementia: A Pilot Randomized Clinical Trial.; Falzarano FB, Greenfield A, Saviano SC, Kolla S, Korian S, Osso F, Miller J, Whitson HE, Maciejewski PK, Prigerson HG; JAMA Network Open, 2026. randomised controlled trial Discussion · source text
-
“The next steps will be to establish the most effective, cost-effective, and feasible strategies for reducing these risks, that can be sustained within local contexts and achieve the best impacts, at the population level, in the short, medium, and long term.”
— Population attributable fractions of modifiable risk factors for dementia: a systematic review and meta-analysis.; Stephan BCM, Cochrane L, Kafadar AH, Brain J, Burton E, Myers B, et al.; Lancet Healthy Longevity, 2024. meta-analysis Discussion · source text
-
“Although we acknowledge that this was a 12-month-duration study, which may be insufficient to definitively establish long-term clinical benefit in Alzheimer’s disease, it can still yield meaningful insights, and further studies are necessary to fully establish the effectiveness of this drug.”
— Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.; Edison P, Femminella GD, Ritchie C, Nowell J, Holmes C, Walker Z, Ridha B, Raza S, Livingston NR, Frangou E, et al.; Nature Medicine, 2025. randomised controlled trial Discussion · source text
Show the other 45 quotes in this theme
Bigger samples and independent replication 27 papers
More people, and someone else repeating it. — 27 quoted sentences from 27 separate papers.
-
“Due to the exploratory nature of this phase 2b study, these findings need to be confirmed in larger studies.”
— Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.; Edison P, Femminella GD, Ritchie C, Nowell J, Holmes C, Walker Z, Ridha B, Raza S, Livingston NR, Frangou E, et al.; Nature Medicine, 2025. randomised controlled trial Discussion · source text
-
“However, whether the latter was more pronounced in women than in men was not examined and requires further investigation by future studies that are adequately powered to detect sex differences.”
— Type 2 Diabetes as a Risk Factor for Dementia in Women Compared With Men: A Pooled Analysis of 2.3 Million People Comprising More Than 100,000 Cases of Dementia.; Chatterjee S, Peters SAE, Woodward M, et al.; Diabetes Care, 2016. meta-analysis Conclusions · source text
-
“While some US cohort studies have observed a significant association between vision impairment and dementia risk [ , ], other US and European longitudinal studies have failed to replicate these findings [ – ].”
— A comprehensive evaluation on the associations between hearing and vision impairments and risk of all-cause and cause-specific dementia: results from cohort study, meta-analysis and Mendelian randomization study.; Jiang F, Dong Q, Wu S, Liu X, Dayimu A, Liu Y, Ji H, Wang L, Liu T, Li N, et al.; BMC Medicine, 2024. meta-analysis Background · source text
-
“Therefore, future studies with larger numbers of vascular dementia cases are needed.”
— Dose-response association between device-measured physical activity and incident dementia: a prospective study from UK Biobank.; Petermann-Rocha F, Lyall DM, Gray SR, Gill JMR, Sattar N, Welsh P, et al.; BMC Medicine, 2021. Strengths and limitations · source text
-
“Further studies using larger numbers of well-characterized AD patients and neuropathological data will thus be required to more precisely delineate the impact of each of the loci on AD pathology versus other neuropathologies.”
— Consensus meta-analysis of genome-wide association studies for Alzheimer's disease and related dementias.; Bellenguez C, Lambert JC, et al.; Nature Genetics, 2026. meta-analysis Main · source text
Show the other 22 quotes in this theme
Specific exposures, drugs and programmes named as worth testing 25 papers
Where authors do not just say 'more research' but name the thing they think should be tested. — 31 quoted sentences from 25 separate papers.
-
“While red wine, a key contributor of anthocyanin intake, has been shown to be beneficial for both dementia and depression at moderate intakes, , the associations among alcohol intake, depression, and dementia are complex, and future studies are needed to further understand these findings.”
— Flavonoid-Rich Foods, Dementia Risk, and Interactions With Genetic Risk, Hypertension, and Depression.; Jennings A, Thompson AS, Tresserra-Rimbau A, O'Neill JK, Hill C, Bondonno NP, et al.; JAMA Network Open, 2024. Discussion · source text
-
“Furthermore, our results on cognitive decline are in accordance with other longitudinal studies showing no association between physical activity and cognitive ageing.”
— Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study.; Sabia S, Dugravot A, Dartigues JF, Abell J, Elbaz A, Kivimäki M, Singh-Manoux A; BMJ, 2017. Strengths and limitations of study · source text
-
“The role of prolonged sleep duration in the development of dementia remains unclear and is closely associated with age.”
— Sleep disorders and the risk of cognitive decline or dementia: an updated systematic review and meta-analysis of longitudinal studies.; Zhang J, Ou J, Lu X, Wang T, Dang W, Ding L, Liu Y, Xu J, Yan B, Yu H; Journal of Neurology, 2025. meta-analysis Sleep duration and cognitive disorders · source text
-
“Further research is needed to investigate semaglutide's effects in patients with obesity, both with and without T2DM.”
— Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.; Wang W, Wang QQ, Qi X, Gurney M, Perry G, Volkow ND, Davis PB, Kaelber DC, Xu R; Alzheimer's & Dementia, 2024. DISCUSSION · source text
-
“However, this previous analysis was not designed to examine the association of olive oil and diet quality with dementia-related mortality, and therefore the latter remains unclear.”
— Consumption of Olive Oil and Diet Quality and Risk of Dementia-Related Death.; Tessier AJ, Cortese M, Yuan C, Bjornevik K, Ascherio A, Wang DD, Chavarro JE, Stampfer MJ, Hu FB, Willett WC, et al.; JAMA Network Open, 2024. Introduction · source text
-
“Future studies should evaluate the influence of suddenly stopping the GLP-1 analogs on the brain after daily injections for a year.”
— Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.; Edison P, Femminella GD, Ritchie C, Nowell J, Holmes C, Walker Z, Ridha B, Raza S, Livingston NR, Frangou E, et al.; Nature Medicine, 2025. randomised controlled trial Discussion · source text
Show the other 25 quotes in this theme
Whether the association is causal is still open 18 papers
Observational signals that the authors themselves decline to call cause and effect. — 18 quoted sentences from 18 separate papers.
-
“Although the analyses were adjusted for the number of components the participants received, future studies could consider testing intervention components with similar dosage and delivery settings to minimize confounding factors.”
— Multicomponent Intervention for Distressed Informal Caregivers of People With Dementia: A Randomized Clinical Trial.; Kwok JYY, Cheung DSK, Zarit S, Cheung KS, Lau BHP, Lou VW, Cheng ST, Gallagher-Thompson D, Qian M, Chou KL; JAMA Network Open, 2025. randomised controlled trial Strengths and Limitations · source text
-
“Future studies will need to confirm underlying mechanisms and should investigate other eye diseases (observationally and in MR studies), including diabetic retinopathy, optic neuropathy, and other vascular causes of eye disease.”
— Visual Impairment, Eye Conditions, and Diagnoses of Neurodegeneration and Dementia.; Ferguson EL, Thoma M, Buto PT, Wang J, Glymour MM, Hoffmann TJ, et al.; JAMA Network Open, 2024. Discussion · source text
-
“Randomized controlled trials are needed to confirm the observational evidence.”
— Comparative dementia risk with GLP1 receptor agonists, SGLT2 inhibitors, or DPP4 inhibitors: a population-based cohort study.; Wu CY, Alkabbani W, Shah BR, Kapral MK, Edwards JD, Maxwell CJ, et al.; Alzheimer's Research & Therapy, 2025. Limitations · source text
-
“The study findings need to be interpreted keeping in mind the observational nature of the data.”
— Alcohol consumption and risk of dementia: 23 year follow-up of Whitehall II cohort study.; Sabia S, Fayosse A, Dumurgier J, Dugravot A, Akbaraly T, Britton A, Kivimäki M, Singh-Manoux A; BMJ, 2018. Strengths and limitations of this study · source text
-
“These considerations highlight the need for further research using more rigorous methodologies, such as phase 2 randomized controlled trials with lower attrition and alternative strategies to mitigate assessment‐related biases.”
— A randomized trial of two online platforms for dementia family caregivers: GamePlan4Care and Resources4Care.; Stevens AB, Cho J, Birchfield T, Reese J, Han G, Thorud JL, Ory MG; Alzheimer's & Dementia, 2025. randomised controlled trial DISCUSSION · source text
-
“The cognitive benefits of cataract surgery should be investigated further in randomized trials.”
— Cataract Surgery and Cognitive Benefits in the Older Person: A Systematic Review and Meta-analysis.; Yeo BSY, et al.; Ophthalmology, 2024. meta-analysis abstract only
Show the other 12 quotes in this theme
Long-term safety and harms 14 papers
Adverse effects over a horizon longer than the trial. — 24 quoted sentences from 14 separate papers.
-
“Further study of CAA‐ri may therefore offer a valuable model for exploring the pathophysiological mechanisms of ARIA.”
— Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup.; van Etten ES, et al.; Alzheimer's & Dementia, 2026. review Spontaneous hemorrhages and edema · source text
-
“Whether the microglial response is harmful, helpful, or both during disease progression remains unclear.”
— APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer's disease.; Nguyen AT, Wang K, Hu G, Wang X, Miao Z, Azevedo JA, Suh E, Van Deerlin VM, Choi D, Roeder K, Li M, Lee EB; Acta Neuropathologica, 2020. Discussion · source text
-
“Any potential benefits of antipsychotic treatment therefore need to be weighed against the risk of serious harm across multiple outcomes.”
— Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study.; Mok PLH, Carr MJ, Guthrie B, Morales DR, Sheikh A, Elliott RA, Camacho EM, van Staa T, Avery AJ, Ashcroft DM; BMJ, 2024. Policy implications · source text
-
“However, the reported variability in sensitivity and specificity values across our 4 laboratories and fair agreement suggest that the next step is to propose international recommendations for the harmonization of the α-syn SAA for clinical use.”
— Diagnostic Performance of the α-Synuclein Seed Amplification Assay for Dementia With Lewy Bodies: A Comparison Across 4 Laboratories.; Kumar R, Gravett S, Jelic V, Lange J, Oftedal L, Ciullini A, Bacınoğlu MB, De Luca CMG, Hamied L, Birck C, et al.; Neurology, 2026. Discussion · source text
-
“Future studies should report more transparently on the impact of ARIA.”
— Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease.; Nonino F, Minozzi S, Sambati L, Del Giovane C, Baldin E, Bassi MC, et al.; Cochrane Database of Systematic Reviews, 2026. meta-analysis Implications for research · source text
-
“Although we observed some harmful effects of APOE4 on lifespan, as observed in ‘the early survival’ and median age at death, which many previous longevity studies primarily evaluate ( ), further studies would be needed to confirm that APOE4 has indeed worse impacts on overall lifespan, compared to APOE3 , as observed in clinical data.”
— APOE2 is associated with longevity independent of Alzheimer's disease.; Shinohara M, Kanekiyo T, Tachibana M, Kurti A, Shinohara M, Fu Y, Zhao J, Han X, Sullivan PM, Rebeck GW, Fryer JD, Heckman MG, Bu G; eLife, 2020. Discussion · source text
Show the other 18 quotes in this theme
The right dose, intensity, frequency and type is unresolved 13 papers
Especially for exercise, diet and other behavioural interventions: something works, but not how much of it. — 15 quoted sentences from 13 separate papers.
-
“However, it remains unclear which specific components or combinations are most effective.”
— Multicomponent Intervention for Distressed Informal Caregivers of People With Dementia: A Randomized Clinical Trial.; Kwok JYY, Cheung DSK, Zarit S, Cheung KS, Lau BHP, Lou VW, Cheng ST, Gallagher-Thompson D, Qian M, Chou KL; JAMA Network Open, 2025. randomised controlled trial Introduction · source text
-
“Of note, some of the higher‐dose cohorts received a single dose of dexamethasone prior to each treatment to minimize infusion reactions; it remains unknown whether this pre‐treatment has any effect on ARIA occurrence, as lower ARIA rates were also observed among participants who did not receive any steroid pre‐treatment.”
— Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup.; van Etten ES, et al.; Alzheimer's & Dementia, 2026. review Brainshuttle · source text
-
“Future studies are needed to confirm current findings, explore the effects of different types of exercise training on outcomes in individuals with SVCI, identify moderators of exercise efficacy (e.g., biological sex), and examine the distinct mechanisms by which each exercise modality may exert its benefits.”
— Resistance training and subcortical vascular cognitive impairment: A 12-month randomized trial.; Liu-Ambrose T, Falck RS, Dao E, Crockett RA, Barha CK, Silva NCBS, et al.; Alzheimer's & Dementia, 2026. randomised controlled trial DISCUSSION · source text
-
“Further studies should be carried out adopting a more rigorous methodology (e.g., randomization strategies) to investigate the effectiveness of COTs, especially CT and CR interventions, and attempting to address the existing heterogeneity, including standardizing interventions, and reporting detailed data on treatment protocols and on the frequency and intensity of interventions.”
— The efficacy of cognitive stimulation, cognitive training, and cognitive rehabilitation for people living with dementia: a systematic review and meta-analysis.; Paggetti A, Druda Y, Sciancalepore F, Della Gatta F, Ancidoni A, Locuratolo N, et al.; GeroScience, 2024. meta-analysis Future directions · source text
-
“However, the current evidence falls short in elucidating the precise dose–response relationship between PA and the incidence of dementia, necessitating further research [ ].”
— Dose- and pattern- physical activity is associated with lower risk of dementia.; Wang Y, Li F, Cao S, Jia J; Journal of Prevention of Alzheimer's Disease, 2025. Introduction · source text
-
“Beyond their diagnostic value, future work will undoubtedly focus on whether amyloid and tau PET can identify optimal responders to various treatments and whether the duration of treatment can be calibrated on the basis of longitudinal changes in PET.”
— Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.; Rabinovici GD, Knopman DS, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O, Herscovitch P, Kuo PH, Lingler JH, Minoshima S, et al.; Alzheimer's & Dementia, 2025. systematic review FURTHER RESEARCH QUESTIONS · source text
Show the other 9 quotes in this theme
When in life to intervene 13 papers
Midlife, preclinical, or after symptoms - the window is contested. — 13 quoted sentences from 13 separate papers.
-
“Future studies should also consider 3‐5 years of long‐term follow‐up, starting from prodromal DLB (mild cognitive impairment with Lewy bodies MCI‐LB), to provide comprehensive coverage of long‐term observations.”
— Long-term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies: An up to 10-year follow-up study.; Xu H, Habich A, Ferreira D, Elisabet L, Westman E, Eriksdotter M; Alzheimer's & Dementia, 2024. DISCUSSION · source text
-
“Although we observed some harmful effects of APOE4 on lifespan, as observed in ‘the early survival’ and median age at death, which many previous longevity studies primarily evaluate ( ), further studies would be needed to confirm that APOE4 has indeed worse impacts on overall lifespan, compared to APOE3 , as observed in clinical data.”
— APOE2 is associated with longevity independent of Alzheimer's disease.; Shinohara M, Kanekiyo T, Tachibana M, Kurti A, Shinohara M, Fu Y, Zhao J, Han X, Sullivan PM, Rebeck GW, Fryer JD, Heckman MG, Bu G; eLife, 2020. Discussion · source text
-
“Future studies in larger community‐based settings may provide additional information on the utility of p‐tau217 in screening for preclinical AD.”
— Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer's disease pathology among cognitively impaired and unimpaired: A systematic review and meta-analysis.; Mohammad Khalafi, William J. Dartora, Laura Beth J. McIntire, Tracy A. Butler, Krista M. Wartchow, Seyed Hani Hojjati, Qolamreza R. Razlighi, Kiarash Shirbandi, Liangdong Zhou, Kewei Chen, Ke Xi, Samprit Banerjee, Nancy Foldi, Silky Pahlajani, Lidia Glodzik, Yi Li, Mony J. de Leon, Gloria C. Chiang; Alzheimer's & Dementia, 2024. meta-analysis Conclusion · source text
-
“Although a recent review assessed prospective longitudinal studies to describe the associations between CR, AD biomarkers, and cognitive/clinical outcomes in participants who were cognitively normal at baseline (i.e., preclinical AD-dementia) (Soldan et al. ), their focus on how CR was related to multiple outcomes including onset of clinical symptoms of MCI, changes in cognition, and changes in AD biomarkers, precluded a quantitative examination and limited conclusions regarding the effect of CR on dementia progression.”
— Cognitive Reserve, Alzheimer's Neuropathology, and Risk of Dementia: A Systematic Review and Meta-Analysis.; Nelson ME, Jester DJ, Petkus AJ, Andel R; Neuropsychology Review, 2021. meta-analysis Focus of the Current Review · source text
-
“Midlife depression has been associated with an increased risk of dementia, but it remains unclear whether this risk is attributable to specific symptoms.”
— Specific midlife depressive symptoms and long-term dementia risk: a 23-year UK prospective cohort study.; Frank P, Singh-Manoux A, Pentti J, Batty GD, Sommerlad A, Steptoe A, et al.; Lancet Psychiatry, 2025. abstract only
Show the other 8 quotes in this theme
Better treatments and interventions still need developing 2 papers
Not whether a thing works, but that no good enough option exists yet. — 2 quoted sentences from 2 separate papers.
-
“Further research is needed into safer drug treatment of behavioural and psychological symptoms of dementia and more efficacious, easy to deliver, initial non-drug treatments.”
— Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study.; Mok PLH, Carr MJ, Guthrie B, Morales DR, Sheikh A, Elliott RA, Camacho EM, van Staa T, Avery AJ, Ashcroft DM; BMJ, 2024. Policy implications · source text
Show the other 1 quote in this theme
Combination and multidomain approaches 1 paper
Whether interventions add up, and which ones to combine. — 1 quoted sentence from 1 separate paper.
-
“However, it remains unclear which specific components or combinations are most effective.”
— Multicomponent Intervention for Distressed Informal Caregivers of People With Dementia: A Randomized Clinical Trial.; Kwok JYY, Cheung DSK, Zarit S, Cheung KS, Lau BHP, Lou VW, Cheng ST, Gallagher-Thompson D, Qian M, Chou KL; JAMA Network Open, 2025. randomised controlled trial Introduction · source text
Other open questions 35 papers
Verbatim suggestions that did not fall into any theme above. They are published rather than discarded so the page does not quietly lose a question an author actually raised. — 47 quoted sentences from 35 separate papers.
-
“While these findings suggest that postmortem CSF SAA results may generally be comparable to those obtained from antemortem samples, further research is needed to fully understand the differences.”
— Two-step detection of Lewy body pathology via smell-function testing and CSF α-synuclein seed amplification.; Mastenbroek SE, Collij LE, Vogel JW, Caldera S, Serrano GE, Adler CH, Vargiu CM, Palmqvist S, Barkhof F, Parchi P, et al.; Nature Communications, 2025. Discussion · source text
-
“These factors should be considered in future studies for a more comprehensive evaluation.”
— Long-term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies: An up to 10-year follow-up study.; Xu H, Habich A, Ferreira D, Elisabet L, Westman E, Eriksdotter M; Alzheimer's & Dementia, 2024. DISCUSSION · source text
-
“Our report pointing at technical variation in α-syn preparation, experimental conditions, and analysis of SAA results may elucidate several areas for improvement in future studies.”
— Diagnostic Performance of the α-Synuclein Seed Amplification Assay for Dementia With Lewy Bodies: A Comparison Across 4 Laboratories.; Kumar R, Gravett S, Jelic V, Lange J, Oftedal L, Ciullini A, Bacınoğlu MB, De Luca CMG, Hamied L, Birck C, et al.; Neurology, 2026. Discussion · source text
-
“Other biomarkers that seem to be more aligned with tau aggregate pathology – including p-tau262 and p-tau356 for soluble tau assemblies [ ] and MTBR tau for fibrils and tangles [ , ] should be investigated in future studies.”
— Head-to-head comparison of plasma p-tau217 immunoassays for incipient Alzheimer's disease in community cohorts.; Rebecca A. Deek, Wasiu G. Balogun, Xuemei Zeng, Gallen Triana-Baltzer, Tharick A. Pascoal, Hartmuth C. Kolb, Beth Snitz, Ann D. Cohen, Thomas K. Karikari; Alzheimer's Research & Therapy, 2026. Discussion · source text
-
“Other factors underlying this finding should be explored in future studies.”
— Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform.; Sebastian Palmqvist, Noëlle Warmenhoven, Federica Anastasi, Andrea Pilotto, and colleagues (multi-site Swedish, Spanish and Italian collaboration); Nature Medicine, 2025. Discussion · source text
-
“Though we observed a significant reduction in AD risk in a high‐risk population with T2DM and also high comorbidity (43% obesity and 77% hypertension), future studies should explore longer follow‐ups and different populations.”
— Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.; Wang W, Wang QQ, Qi X, Gurney M, Perry G, Volkow ND, Davis PB, Kaelber DC, Xu R; Alzheimer's & Dementia, 2024. DISCUSSION · source text